ABL is pleased to announce the official release of its SeqHepB v6 interpretation system & database. Dedicated to the management of Viral Hepatitis B (HBV) sequencing data, the software can handle Capillary Electrophoresis or Next Generation Sequencing data, performs genotyping and mutation detection analyses of Polymerase, HBsAg, Core, Pre-core, Pre-S1, Pre-S2, X genes and is also compatible with Whole Genome analysis. It provides a comprehensive list of clinical interpretations including drug resistance, vaccine escape assessments or advanced liver disease prognosis.
SEQHEPB V6 – The Largest HBV Interpretation System & Database
Renewal and Extension of the partnership with ThermoFisher around virology genotyping.
ABL is pleased to announce the renewal and the extension of the Reseller rights given to ThermoFisher to promote ABL’s Capillary Electrophoresis sequencing data analysis software (ViroScore®), on a worldwide basis (except Spain). The platform is intended to be used for genotyping in Virology with a focus on multiple applications including : HIV, HBV, HCV, CMV, and soon HPV and other viruses.
Studies on DeepChek®-HCV Assays presented at the EASL 2017
- “Evaluation of a sequence-based method for hepatitis C genotyping (DeepChek® SingleRound PCR and NS5B/5’UTR sequencing) and comparison with VERSANT HCV Genotype 2.0 assay (InnoLiPA)” – Greet J. Boland et al. – EASL 2017 – See poster
- “Retreatment with Direct Active Antivirals of Genotype 1, 3 and 4 Chronic Hepatitis C Patients who Previously Failed an Anti-NS5A-Containing Regimen in Real World” – P. Halfon et al. – EASL 2017 – See poster
New patent issued in Hong Kong around HBV resistance announced!
Advanced Biological Laboratories has been granted additional patents in Hong Kong (HK1121187) to further protect its intellectual property and reinforce the already existing core patent entitled ”
Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof” (US Patent 8,367,317, Publication nº US8367317 B2).
ABL Welcomes You at the EASL in Amsterdam (April 19th – 22nd 2017)
Our team will provide information on our portfolio:
Laboratories, virologists and microbiologists:
- DeepChek® Assays (Genotyping & Drug Resistance)
- UltraGene® Assays (Viral Load Detection)
- DeepChek®, SeqHepB® (Software systems for Sanger or NGS sequencing data management)
- Application: HBV, HCV…
Clinics, clinicians and pathologists:
- Electronic Medical Record systems for HBV/HCV patients management (Nadis® and TherapyEdge®)
- Registries for HCV/HBV patients monitoring, epidemiological studies (HepatiC®, …)
Latest updates on ABL’s HIV Assays Portfolio
ABL is delighted to announce the outcomes of a National Quality Control Study performed on the DeepChek® HIV Assays (RT/PR and INTEGRASE) on a panel human plasma samples collected in 2015 in 56 different labs in France. The overall agreement in the detection of HIV virus mutations exceeded 99% compared to the expected results with a 100% sensitivity (percentage of positions defined as mutated among real mutated positions) and a specificity (percentage of positions defined as “wild-type” compared to real “wild-type” positions) >99%. Those assays combine target-specific PCR reagents with in vitro diagnostic software both compatible with either Sanger or Next Generation Sequencing platforms for HIV genotyping.
In addition to its DeepChek® Assays, ABL is pleased to announce the release of a new line of molecular biology products, called UltraGene-HIV, during the second quarter of 2017, intended to be primarily used for HIV viruses’ viral load detection and which can also be used for genotyping through Next Generation Sequencing.
Please contact us (contact@ablsa.com) for more information.
About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL’s products also received CE-marking for IVD use. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL’s DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.
Technogenetics to Offer ABL’s Genotyping Products in Italy
Advanced Biological Laboratories (ABL) S.A. and Technogenetics (TGX) today announced that they entered into an exclusive distributor agreement of the DeepChek® SingleRound Assay and software product lines in Italy. The DeepChek® SingleRound Assay product line combines target-specific PCR reagents with in vitro diagnostic software, both compatible with either Sanger or Next Generation Sequencing platforms for Virology applications (like HIV, Hepatitis C, Hepatitis B first, then for HPV, CMV, Flu, Herpes and Tuberculosis).
ABL acquires Fedialis Medica
ABL continues developing its technology offer with Nadis(r) technology as a specialized patient management system. Nadis is widely used in France, this completes the offer for the French market in plus of microbiology reagents and software.
New Diagnostics Test and Technology for Hepatitis C
ABL inked an agreement with Inserm on a test and related IP and know-how intended for viral hepatitis C.
Combining Ion Torrent sequencing systems and the DeepChek Suite Software
ABL is pleased to invite you to attend the viral typing webinar held with Thermo Fisher Scientific about the combination of their next generation sequencing systems and the ABL DeepChek downstream analysis software, for HIV, HBV and HCV. Tuesday, 10th May 2016 — 5 pm CET / 4 pm GMT / 11 am EST Register now for this free viral typing webinar.
New commercial agreement for ViroScore® and DeepChek®
ABL inked a distribution agreement with Thermo Fisher Scientific for ViroScore and DeepChek, downstream analysis softwares for Sanger and Next Generation Sequencing respectively. These are also available on Thermo Fisher Cloud. See the press release.
ABL Group launches early access program
ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group’s offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, ViroScore® and DeepChek®. To know more, please click here.
A methodology to help doctors choosing the most efficient treatment for hepatitis C
Barcelona, 16th February 2015. Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations.
The study, published in the Journal of Clinical Microbiology, is a collaboration between all the members of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Roche and ABL. It is funded with the CDTI MINECO IDI 20110115.
HepatiC® trademark registration
ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252. The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antiviral Agents which has been developed together with the Spanish Association for Liver Diseases.
ABL signs agreement with UH Case Medical Center to offer HIV drug resistance tests
University Hospitals (UH) Case Medical Center has signed an agreement with Advanced Biological Laboratories (ABL), to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS). See the press release.
https://sg.finance.yahoo.com/news/advanced-biological-laboratories-signs-agreement-130000299.html
http://www.eurekalert.org/pub_releases/2015-01/uhcm-abl011315.php
University Hospitals signs agreement with Luxembourg company to offer new HIV drug resistance test.